Arg-Gly-Asp (RGD) peptides alter hepatic killing of Candida albicans in the isolated perfused mouse liver model.
The isolated perfused mouse liver model was used to study the effect of Arg-Gly-Asp (RGD)-containing peptides on hepatic trapping and killing of Candida albicans. After extensive washing, 10(6) C. albicans CFU were infused into mouse livers. At the time of recovery, 63% +/- 2% (mean +/- standard error of the mean) of the infused C. albicans CFU were recovered from the liver and 14% +/- 1% were recovered from the effluent for a total recovery of 77% +/- 2%. This indicates that 86% +/- 9% of the original inoculum was trapped by the liver and that 23% +/- 2% was killed within the liver. Prior to their infusion into livers, 10(7) CFU of C. albicans were incubated at 37 degrees C for 30 min in the presence of various RGD peptides (0.1 mg/ml). Repeatedly, more than 90% of the infused RGD-treated C. albicans was trapped by the perfused liver. In comparison with the 23% killing rate observed in control livers, perfused livers killed approximately 40 to 50% of the infused C. albicans treated either with fibronectin, PepTite 2000, RGD, or RGDS. Hepatic killing of C. albicans treated with PepTite 2000 or fibronectin was dose dependent. Treatment of C. albicans with GRGDTP, GRGDSP, GRADSP, or GRGESP did not alter the ability of the perfused liver to kill C. albicans, suggesting that a degree of specificity for RGD peptides is associated with an increased ability of liver to kill RGD-treated C. albicans. Together, the data suggest that RGD peptides bind to a receptor on the surface of C. albicans, thereby increasing hepatic, and presumably Kupffer cell, killing of C. albicans. Natural or synthetic RGD peptides may serve as opsonins promoting C. albicans killing by Kupffer cells.
Sawyer
R T
RT
Division of Biomedical Science, Mercer University School of Medicine, Macon, Georgia 31207.
Garner
R E
RE
Hudson
J A
JA
D000595:Amino Acid Sequence; D000818:Animals; D001422:Bacterial Adhesion; D002177:Candidiasis / Q000503:physiopathology*; D003602:Cytotoxicity, Immunologic / Q000187:drug effects*; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D005353:Fibronectins / Q000494:pharmacology; D008099:Liver / Q000187:drug effects / Q000276:immunology* / Q000382:microbiology; D051379:Mice; D008969:Molecular Sequence Data; D009842:Oligopeptides / Q000494:pharmacology*; D009924:Organ Culture Techniques; D010455:Peptides / Q000494:pharmacology; D010477:Perfusion; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D011971:Receptors, Immunologic
D005353:Fibronectins; D009842:Oligopeptides; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D011971:Receptors, Immunologic; C047981:arginyl-glycyl-aspartic acid; C046617:arginyl-glycyl-aspartyl-serine